Amgen

Biotechnology
AMGN
$ 227 (0.34)%
Share price
$ 121 bn
Market Cap
$ 151 bn
Enterprise Value

Carbon footprint

1.3 Ton
GHG emissions per $ 1 mln investment
0.03x the weighted average for S&P 500
FY2021
How is this calculated?
-31%
YOY change in GHG emissions
Weaker than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-17%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Amgen aims to achieve carbon neutrality for Scope 1 + 2 by 2027


1.5°C
Amgen's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Amgen's GHG emissions (market-based) (Kt of CO2e)
Amgen's Carbon intensity (Tons per 1 USDm)

Amgen's carbon footprint

Amgen reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 191 Kt (-84 /-30.5% y-o-y). Also positively, carbon intensity tumbled to 7.4 t (-3.4 /-31.5% y-o-y).

Amgen's Scope 3 emissions skyrocketed to 3,065 Kt (+438/+17% y-o-y). There has been no clear trend lately.

The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2027, which translates into the estimated reduction of -32 Kt per annum over the period of FY2022 - FY2027. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Amgen aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2027. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...